Q-omics provides the consensus-scored ITGA11 profile across patient tissues and cancer cell-line models. ITGA11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ITGA11 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ITGA11 RNA expression shows 17,866 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, COAD, and BRCA as cancer lineages where ITGA11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGA11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGA11 survival associations across molecular data types. ITGA11 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGA11 RNA expression–survival associations across cancer types. High ITGA11 expression shows unfavorable associations in KIRP, MESO, LGG, BLCA and STAD, but favorable associations in DLBC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ITGA11 RNA expression.
This table summarizes ITGA11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ITGA11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGA11 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, STAD, LUAD and LUSC. The COAD box plot shows higher ITGA11 RNA expression in tumor versus normal tissue (log2 FC = +2.100, t-test p < 0.001).
This table shows molecular features associated with ITGA11 in patient tissues and cancer cell lines. In patient samples, ITGA11 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGA11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
